UnicoCell Biomed, a key player in the field of regenerative medicine, has officially launched its plan to transfer its listing to Taiwan’s main board. The company is currently focused on regenerative treatments for irreversible diseases. Among its core pipelines, the chronic kidney disease (CKD) therapy is expected to file for a Phase III clinical trial in Taiwan next year, while overseas licensing discussions are also underway. In addition, patient enrollment for its Phase III clinical trial targeting knee osteoarthritis is anticipated to be completed by the end of this year. Meanwhile, UnicoCell is expanding the scientific data surrounding its exosome technology for both aesthetic and therapeutic applications, broadening the scope of its raw material offerings.
Read more
